Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Immunosuppressive activities of adenosine in cancer

(2016) Bertrand Allard et al.   CURRENT OPINION IN PHARMACOLOGY

CD73–adenosine: a next-generation target in immuno-oncology

(2016) David Allard et al.   Immunotherapy

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

(2016) James C. Geoghegan et al.   mAbs

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

(2016) Akio Ohta   Frontiers in Immunology

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

(2014) A. Young et al.   Cancer Discovery

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells

(2013) M. G. Terp et al.   JOURNAL OF IMMUNOLOGY

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutrophils as effector cells for antibody-based immunotherapy of cancer

(2013) Marjolein van Egmond et al.   SEMINARS IN CANCER BIOLOGY

CD73-Deficient Mice Are Resistant to Carcinogenesis

(2012) J. Stagg et al.   CANCER RESEARCH

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression

(2011) Gennady G. Yegutkin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

(2011) Long Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fc RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

(2010) F. Nimmerjahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA